PRESS RELEASE published on 09/17/2025 at 14:00, 10 months 24 days ago Inside Information / Other news releases Medincell and Teva to discuss Phase 3 Olanzapine LAI data from SOLARIS Trial at 2025 Psych Congress. Webcast details available on Teva's IR website Phase 3 Medincell Teva SOLARIS Trial Olanzapine LAI
BRIEF published on 09/12/2025 at 07:35, 11 months ago Medincell Appoints Three New Board Members Innovation Biopharmaceutical Leadership Board Appointments Medincell
PRESS RELEASE published on 09/12/2025 at 07:30, 11 months ago Inside Information / Other news releases Medincell appoints Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to its Board of Directors, adding valuable expertise in biotech and pharmaceutical sectors Board Of Directors Medincell Dr. Sharon Mates Dr. Charles Kunsch Dr. Pascal Touchon
BRIEF published on 09/10/2025 at 21:46, 11 months 1 day ago UZEDY® Obtains Approval in South Korea Following Success in the United States Schizophrenia UZEDY Teva Handok Medical Supply Korean Market
PRESS RELEASE published on 09/10/2025 at 21:41, 11 months 1 day ago Inside Information / Other news releases Teva Handok announces regulatory approval for UZEDY® in South Korea by Ministry of Food and Drug Safety, following successful US launch. Medincell's long-acting injectable for schizophrenia shows strong commercial performance Regulatory Approval Schizophrenia Medincell Commercial Performance Teva Handok
BRIEF published on 08/04/2025 at 14:05, 1 year ago Medincell Announces its 2025 General Meeting Governance General Meeting Resolutions Remuneration Medincell
BRIEF published on 07/30/2025 at 14:34, 1 year ago Medincell's Rising Revenue and Upcoming Submissions Schizophrenia Treatment Teva Partnership Medincell Revenue UZEDY Sales Olanzapine Submission
PRESS RELEASE published on 07/30/2025 at 14:29, 1 year ago INSIDE INFORMATION / OTHER NEWS RELEASES Medincell's partner Teva Pharmaceuticals raises 2025 revenue outlook for UZEDY® to $190–$200M and confirms Olanzapine LAI on track for submission in 2025 Revenue Outlook Medincell Teva Pharmaceuticals Olanzapine LAI Submission
BRIEF published on 07/30/2025 at 13:47, 1 year ago Medincell's UZEDY® and Olanzapine LAI Forecast Promising Financial Outcomes Schizophrenia Treatment Teva Pharmaceuticals Medincell Revenue Forecast UZEDY® Performance Olanzapine LAI Development
PRESS RELEASE published on 07/30/2025 at 13:42, 1 year ago Inside Information / Other news releases Medincell's partner Teva increases 2025 revenue outlook for UZEDY® to $190–$200M, plans olanzapine LAI submission. Company's innovative treatments aim to improve medicine accessibility Revenue Outlook Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
Published on 08/12/2026 at 13:45, 6 minutes ago Amarc Announces Geophysical Surveys Identifying Major New Sulphide Mineralized Systems Adjacent To The Aurora Porphyry Copper-Gold Discovery
Published on 08/12/2026 at 13:00, 51 minutes ago Rocky Shore Identifies the Mosquito Target Horizon at the Gold Anchor Project
Published on 08/12/2026 at 12:30, 1 hour 21 minutes ago Relevant Gold Commences 5,000-Metre Drill Program and Updates Exploration Model at the Lewiston Project in Wyoming, USA
Published on 08/12/2026 at 11:30, 2 hours 21 minutes ago American Critical Minerals Announces the Execution of the Drilling Contract with Drake Well Service and Mobilization to the Green River Project
Published on 08/12/2026 at 13:38, 12 minutes ago Nebius reports second quarter 2026 financial results
Published on 08/12/2026 at 12:21, 1 hour 30 minutes ago EQS-Adhoc: Klöckner & Co SE: Delisting will take effect on August 12, 2026 in accordance with the resolution of the Frankfurt Stock Exchange
Published on 08/12/2026 at 11:50, 2 hours 1 minute ago German Offtake Partner to Double Volumes to 40,000 tpa
Published on 08/12/2026 at 11:47, 2 hours 3 minutes ago SME bond market H1 2026: Issuance activity picks up, placement becomes more challenging
Published on 08/10/2026 at 18:00, 1 day 19 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 11:53, 2 days 1 hour ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
Published on 08/10/2026 at 11:36, 2 days 2 hours ago GUILLEMOT CORPORATION| Weekly report share buyback from August 3 to August 7 2026
Published on 08/10/2026 at 09:22, 2 days 4 hours ago Number of shares and voting rights - July 2026 (In French only)
